Advances in the understanding and management of T-cell prolymphocytic leukemia

Laribi, Kamel; Lemaire, Pierre; Sandrini, J.; Materre, Alix Baugier de

doi:10.18632/oncotarget.22272

Cited by 24 publications

(29 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…) . Lymphopoiesis starts with progenitor cells expressing CD2, CD5, CD7, and cytoplasmic CD3, which have the capacity to enter the cortex of the thymus . At this point, TCRs are formed after rearrangements of α, β, γ, and δ chains resulting in T cells with γδ‐chains (T‐γδ) and T cells with αβ‐chains (T‐αβ).…”

mentioning

confidence: 99%

Comprehensive Phenotyping of T Cells Using Flow Cytometry

et al. 2019

View full text Add to dashboard Cite

The T cell compartment can form a powerful defense against extrinsic (e.g., pathogens) and intrinsic danger (e.g., malignant cells). At the same time, specific subsets of T cells control this process to keep the immune system in check and prevent autoimmunity. A wide variety in T cell functionalities exists, which is dependent on the differentiation and maturation state of the T cells. In this review, we report an overview for the identification of CD4 + T-αβ cells (T-helper (Th)1, Th2, Th9, Th17, Th22, and CD4 + regulatory T cells), CD8 + T-αβ cells (cytotoxic T lymphocyte (Tc)1, Tc2, Tc9, Tc17, and CD8 + regulatory T cells), and their additional effector memory status (naïve, stem cell memory, central memory, effector memory, and effector) using flow cytometry. These different subsets can be discriminated based on selective extracellular markers, in combination with intracellular transcription factor and/or cytokine stainings. Additionally, identification of very small subsets, including antigen-specific T cells, and important technical considerations of flow cytometry are discussed. Together, this overview can be used for comprehensive phenotyping of a T cell subset of interest.

show abstract

mentioning

confidence: 99%

Comprehensive Phenotyping of T Cells Using Flow Cytometry

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The leukemic lymphocytes in T-PLL are usually CD4+/CD8-, however, significant number are doubly positive for CD4 and CD8, or are positive for CD8 and rarely are doubly negative for CD4 and CD8. CD7 is usually expressed in T-PLL [6]. CD7 expression help in diagnosis of T-PLL as it is usually downregulated or lost in most other T cell neoplasms.…”

Section: Discussionmentioning

confidence: 99%

T Prolymphocytic Leukemia, a rare disease, case presentation with typical pathological findings and review of management

Abdulla¹,

Ibrahim²,

Aldapt³

et al. 2018

IJCR

View full text Add to dashboard Cite

“…Alemtuzumab (Campath-1H) is a chimeric humanized antibody that binds to a glycoprotein (CD52), which is highly expressed on benign and malignant B and T-lymphocytes and monocytes (Buggins et al, 2002). Alemtuzumab showed an antitumor activity in various cancer types such as T-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia (Laribi et al, 2017). In ATL, a phase 2 clinical study using Alemtuzumab in acute, chronic, and lymphoma subtypes resulted in an ORR of 52%, mostly in the blood, but unfortunately with a short duration of response (Sharma et al, 2017, reviewed in Hermine et al, 2018.…”

Section: Alemtuzumabmentioning

confidence: 99%

Novel Treatments of Adult T Cell Leukemia Lymphoma

et al. 2020

View full text Add to dashboard Cite

Adult T cell leukemia-lymphoma (ATL) is an aggressive malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-I) retrovirus. ATL carries a dismal prognosis. ATL classifies into four subtypes (acute, lymphoma, chronic, and smoldering) which display different clinical features, prognosis and response to therapy, hence requiring different clinical management. Smoldering and chronic subtypes respond well to antiretroviral therapy using the combination of zidovudine (AZT) and interferon-alpha (IFN) with a significant prolongation of survival. Conversely, the watch and wait strategy or chemotherapy for these indolent subtypes allies with a poor long-term outcome. Acute ATL is associated with chemo-resistance and dismal prognosis. Lymphoma subtypes respond better to intensive chemotherapy but survival remains poor. Allogeneic hematopoietic stem cell transplantation (HSCT) results in long-term survival in roughly one third of transplanted patients but only a small percentage of patients can make it to transplant. Overall, current treatments of aggressive ATL are not satisfactory. Prognosis of refractory or relapsed patients is dismal with some encouraging results when using lenalidomide or mogamulizumab. To overcome resistance and prevent relapse, preclinical or pilot clinical studies using targeted therapies such as arsenic/IFN, monoclonal antibodies, epigenetic therapies are promising but warrant further clinical investigation. Anti-ATL vaccines including Tax peptide-pulsed dendritic cells, induced Tax-specific CTL responses in ATL patients. Finally, based on the progress in understanding the pathophysiology of ATL, and the riskadapted treatment approaches to different ATL subtypes, treatment strategies of ATL should take into account the host immune responses and the host microenvironment including HTLV-1 infected non-malignant cells. Herein, we will provide a summary of novel treatments of ATL in vitro, in vivo, and in early clinical trials.

show abstract

Advances in the understanding and management of T-cell prolymphocytic leukemia

Cited by 24 publications

References 125 publications

Comprehensive Phenotyping of T Cells Using Flow Cytometry

Comprehensive Phenotyping of T Cells Using Flow Cytometry

T Prolymphocytic Leukemia, a rare disease, case presentation with typical pathological findings and review of management

Novel Treatments of Adult T Cell Leukemia Lymphoma

Contact Info

Product

Resources

About